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To understand the effect of previous malaria exposure on antiparasite immune responses is important for developing successful
immunization strategies. Controlled human malaria infections (CHMIs) using cryopreserved Plasmodium falciparum sporozo-
ites provide a unique opportunity to study differences in acquisition or recall of antimalaria immune responses in individuals
from different transmission settings and genetic backgrounds. In this study, we compared antiparasite humoral and cellular im-
mune responses in two cohorts of malaria-naive Dutch volunteers and Tanzanians from an area of lowmalarial endemicity, who
were subjected to the identical CHMI protocol by intradermal injection of P. falciparum sporozoites. Samples from both trials
were analyzed in parallel in a single center to ensure direct comparability of immunological outcomes. Within the Tanzanian
cohort, we distinguished one group with moderate levels of preexisting antibodies to asexual P. falciparum lysate and another
that, based on P. falciparum serology, resembled the malaria-naive Dutch cohort. Positive P. falciparum serology at baseline
was associated with a lower parasite density at first detection by quantitative PCR (qPCR) after CHMI than that for Tanzanian
volunteers with negative serology. Post-CHMI, both Tanzanian groups showed a stronger increase in anti-P. falciparum anti-
body titers than Dutch volunteers, indicating similar levels of B-cell memory independent of serology. In contrast to the Dutch,
Tanzanians failed to increase P. falciparum-specific in vitro recall gamma interferon (IFN-) production after CHMI, and in-
nate IFN- responses were lower in P. falciparum lysate-seropositive individuals than in seronegative individuals. In conclu-
sion, positive P. falciparum lysate serology can be used to identify individuals with better parasite control but weaker IFN- re-
sponses in circulating lymphocytes, whichmayhelp to stratify volunteers in futureCHMI trials in areaswheremalaria is endemic.
In 2012, Plasmodium falciparummalaria caused an estimated 207million cases and 627,000 deaths, of which 90% occurred in
children under 5 years of age and in pregnant women in sub-
Saharan Africa (1). Major control efforts have been implemented
with some success (2, 3), butmalaria eradicationwill likely require
a safe and highly protective vaccine. Subunit vaccines have thus far
shown moderate efficacy at best. RTS,S is the only vaccine candi-
date in phase 3 trials but, despite averting substantial numbers of
malaria cases (4), shows only 30 to 50% reduction in clinical dis-
ease after 12months depending on both age andmalaria endemic-
ity and even less after 18 months (5–7). These results stress the
need for more effective second-generation vaccines. Key require-
ments are not only the identification of novel immunogens but
also a better understanding of protection-related immune re-
sponses. This includes the effect of previous malaria exposure on
immune responses upon reexposure or vaccination (8, 9).
During the past 3 decades, controlled humanmalaria infection
(CHMI) trials have become an indispensable tool not only in as-
sessing the efficacy of candidate vaccines (10, 11) but also in eval-
uating immune responses induced by exposure to themalaria par-
asite (12–15). CHMI trials have so far been performed in countries
were malaria is not endemic in previously unexposed individuals
(11, 16–19). A logical next step is to study the potential differences
in the acquisition, maintenance, or recall of immune responses in
individuals from different transmission settings and genetic back-
grounds (20, 21). The availability of aseptic, purified, cryopre-
served, live P. falciparum sporozoites (PfSPZs; PfSPZ Challenge)
(22) opens up opportunities to carry out CHMI trials in countries
where malaria is endemic, since it bypasses the need for infecting
local Anopheles mosquitoes with P. falciparum or importing P.
falciparum-infected mosquitoes to the trial site. The first PfSPZ
Challenge trial in malaria-naive Dutch volunteers demonstrated
an infectivity rate of 83% after intradermal injections, indepen-
dent of the dose given (23). Recently, PfSPZ Challenge was used
for the first time during a CHMI trial in healthy adult male Tan-
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zanian volunteers, resulting in similar infection rates (24). As a
follow-up, we here present results of themalaria-specific humoral
and cellular immune responses in Tanzanians and Dutch volun-
teers who were inoculated intradermally with the same number of
live PfSPZs during these CHMI studies.
MATERIALS AND METHODS
Human ethics statement. The Dutch trial (23) was approved by the Cen-
tral Committee for Research Involving Human Subjects of The Nether-
lands (NL31858.091.10) and registered at Clinicaltrials.gov, identifier
NCT 01086917. The Tanzanian trial (24) was approved by institutional
review boards of the Ifakara Health Institute (IHI/IRB/No25), the Na-
tional Institute for Medical Research Tanzania (NIMR/HQ/R.8a/Vol.IX/
1217), the Ethikkommission beider Basel (EKBB), Basel, Switzerland
(EKBB 319/11), and the Tanzanian Food and Drug Administration (ref-
erence no. CE.57/180/04A/50) and registered at Clinicaltrials.gov, identi-
fier NCT 01540903. All study teams complied with the Declaration of
Helsinki and good clinical practice, including monitoring of data, and all
volunteers gave written informed consent.
Clinical trial design. Samples for immunological analysis were ob-
tained from two CHMI trials (23, 24).
The first trial, performed at Radboud University Medical Center, Ni-
jmegen, The Netherlands, was composed of 18 healthy Dutch subjects
between the ages of 19 and 30 years with no history of malaria. Any vol-
unteer who was positive for P. falciparum serology or had resided in an
area wheremalaria is endemic within the previous 6months was excluded
from the trial. Three groups (n 6 per group) were infected by intrader-
mal injections of 2,500, 10,000, or 25,000 cryopreserved PfSPZs (NF54
strain). By day 21, 15/18 volunteers had developed parasites detectable by
positive blood thick smear (TS), 5/6 in each group (23). There were no
differences in parasite densities at diagnosis between the three dose groups
(23). For immunological analysis, nine P. falciparum-positive volunteers
of the 10,000 (n 4) and 25,000 (n 5) PfSPZ dose groups were selected
based on availability of plasma and peripheral blood mononuclear cells
(PBMCs).
The second trial was carried out in Bagamoyo, Tanzania, with volun-
teers residing in Dar es Salaam (an area where malaria is hypoendemic).
Twenty-four males between 20 to 35 years of age were enrolled and con-
firmed to be free of parasites by real-time quantitative PCR (qPCR). Sub-
jects with a self-reported history of clinical malaria in the previous 5 years
were excluded. The volunteers were divided into two groups with 12 vol-
unteers per group and infected by intradermal injections of either 10,000
or 25,000 PfSPZs (NF54 strain). A total of 21/24 became both qPCR and
blood smear positive by day 21 after infection (24). The three P. falci-
parum-negative volunteers were excluded from analysis in the present
study.
PBMCs, citrate anticoagulated plasma samples from Dutch volun-
teers, and serum samples from Tanzanian volunteers were collected and
cryopreserved 1 day before challenge (pre-CHMI) and after treatment
(post-CHMI; day 35 and day 28 after infection).
DNA extraction and qPCR analysis. A total of 5 l Zap-Oglobin II
lytic reagent (BeckmanCoulter) was added to 500l of EDTAblood, after
which the samples were mixed and stored at80°C.
DNA extraction and quantification of parasitemia by qPCR in the
Dutch CHMI trial were performed in Nijmegen as described previously
(25), with slightmodifications. Briefly, after thawing, samples were spiked
with murine white blood cells as an extraction control, and DNA was
extracted with a MagnaPure LC isolation station. For detection of the
extraction control and P. falciparum, primers for the murine albumin
gene and P. falciparum 18R rRNA were used as described previously (25).
Additionally, the P. falciparum 18R rRNATaqManMGBprobe AACAAT
TGG AGG GCA AG–6-carboxyfluorescein (FAM) was used.
DNA extraction and qPCR in the Tanzanian trial were carried out at
the Leiden University Medical Center, Leiden, The Netherlands, as de-
scribed previously (26). Phocine herpesvirus 1 (PhHV-1)was added to the
isolation lysis buffer to serve as an internal control. For quantification of
PhHV, the primers GGGCGAATCACAGATTGAATC and GCGGTTCC
AAACGTACCAAand the probeCy5-TTTTTATGTGTCCGCCACCATC
TGGATC were used.
P. falciparum (NF54 strain) standard curves for both qPCRassayswere
prepared in Nijmegen by titration of ring-stage-infected red blood cells
(RBC) in uninfected human blood. The two qPCR assays in both sites
were confirmed to yield the same results when quantifying the P. falcipa-
rum content in sequential samples from four CHMI volunteers.
Parasite material for immunological analysis. The P. falciparum
NF54 strain used in both CHMI trials is the parental strain of the 3D7
clone (27). P. falciparum (NF54 strain) blood-stage parasites were cul-
tured in RPMI 1640 containing 10% human A serum and a 5% hemat-
ocrit erythrocyte suspension in a semiautomated culture system and reg-
ularly screened for mycoplasma contamination. For in vitro stimulation
assays, asynchronous parasites harvested at a parasitemia of approxi-
mately 10 to 20%were purified by centrifugation on a 63%Percoll density
gradient to obtain mature asexual stages. This resulted in concentrations
of parasitemia levels of about 80 to 90%, consisting of more than 95%
schizonts/mature trophozoites.P. falciparum-infectedRBC (PfRBC)were
washed twice in RPMI, cryopreserved in glycerol-containing freeze me-
dium, and used upon thawing in stimulation assays. Mock-cultured unin-
fected erythrocytes (uRBC)were obtained similarly and served as the control.
P. falciparum lysate for enzyme-linked immunosorbent assay (ELISA)
was prepared by extracting purified schizonts/mature trophozoites with
1% sodium desoxycholate and 2.5 l phenylmethanesulfonyl fluoride
protease inhibitor for 15 min at room temperature (RT).
Recombinant and synthetic proteins. Recombinant proteins of cir-
cumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were used
to probe humoral responses toward preerythrocytic stages, while crude P.
falciparum lysates were used to assess antibody reactivity toward blood
stages. Apical membrane protein 1 (AMA-1) and exported protein 1
(EXP-1) are expressed in both preerythrocytic and asexual stages.
Full-length P. falciparum NF54 CSP with repeats was produced in
Escherichia coli by Gennova Biopharmaceuticals Ltd., Pune, India. A re-
combinant LSA-1 construct, LSA-NRC, was expressed in E. coli, incorpo-
rating the N- and C-terminal regions of the protein and two of the cen-
trally placed 17-amino-acid repeats for the 3D7 LSA-1 sequence
(PlasmoDB-PF3D7_1036400) (28). Both the N- and C-terminal regions
as well as the repeats are highly conserved between NF54 and 3D7. The
major difference is the greater number of repeats, which are the primary
target of anti-LSA-1 antibodies (29), in the NF54 sequence than in the
3D7 sequence (30). Amino acids 25 to 545 of codon-optimized AMA-1 of
the P. falciparum FVO strain were expressed in the methylotrophic yeast
Pichia pastoris (31, 32). A peptide covering the C-terminal amino acids 73
to 162 of the integral parasitophorous vacuolar membrane protein EXP-1
(Swiss-Prot Database primary accession number P04926) was chemically
synthesized using solid-phase 9-fluorenylmethoxy carbonyl (Fmoc)
chemistry and differs from the 3D7 sequence only by a single amino acid
in position 160 (33).
ELISA to assess antibody reactivity.Ninety-six-well Polystyrene flat-
bottom plates (Nunc Maxisorp; Thermo Scientific) were coated with 2
g/ml of CSP, EXP-1, and AMA-1, 0.25 g/ml of LSA-1, or P. falciparum
lysate at the equivalent of 20,000 PfRBC/well in phosphate-buffered saline
(PBS) and incubated overnight at 4°C. Plates were blocked with 5% milk
in PBS. All of the following washing steps were carried out with PBS-
0.05% Tween (PBST). Using 1%milk in PBST, plasma or serum samples
were serially diluted in duplicate starting at 1:50 to 1:800 for protein an-
tigen and 1:250 to 1:4,000 for P. falciparum lysate and incubated for 3 h at
room temperature. Bound IgGwas detected using horseradish peroxidase
(HRP)-conjugated anti-human IgG (Thermo Scientific; diluted 1:60,000 in
sample buffer). Plates were developed using tetramethylbenzidine (TMB)
peroxidase substrate (tebu-bio). The reaction was stopped using an equal
volume of 0.2 M H2SO4, and absorbance was measured with a spectropho-
tometer plate reader at 450 nm (Anthos 2001 ELISA plate reader).
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A serial dilution of a pool of sera from 100 hyperimmune Tanzanian
(HIT) (20) individuals living in an area where malaria is highly endemic
was used as a reference standard and was included on each plate. The
reactivity for each antigen in undiluted HIT serum was defined as 100
arbitrary units (AUs). Optical density (OD) values were converted into
AUs by using the four-parameter logistic curve fit using the Auditable
Data Analysis andManagement System for ELISA (ADAMSEL-v1.1; http:
//www.malariaresearch.eu/content/software).
For each antigen, all time points of an individual volunteer were as-
sayed on the same plate. To determine whether Tanzanians had a positive
P. falciparum serology (by recognition of P. falciparum lysate), the mean
(2 standard deviations [SD]) baseline antibody titer against P. falcipa-
rum lysate of the Dutch volunteers was used as the cutoff for positivity.
In vitro PBMC stimulation assay to assess cellular responses. Ve-
nous whole blood was collected into citrated Vacutainer CPT cell prepa-
ration tubes (Becton Dickinson). PBMCs were obtained by density gradi-
ent centrifugation, washed three times in cold PBS, counted, frozen at 107
cells/ml in fetal calf serum (FCS) with 10% dimethyl sulfoxide, and stored
in vapor-phase nitrogen. After being thawed, PBMCs were counted and
cultured at a concentration of 500,000 cells/well in a 96-well round-bot-
tom plate and stimulated in duplicate at a ratio of 1:2 with 106 P. falcipa-
rum NF54-infected RBC or uRBC for either 24 h or 6 days in a total
volume of 200 l.
Flow cytometry. Cells were stained and analyzed by flow cytometry
either directly ex vivo or after 24 h or 6 days of in vitro stimulation. Cells
were stained first for viability with LIVE/DEAD fixable Aqua dead cell
stain (Invitrogen) or fixable viability dye eFluor 780 (eBioscience) and
later with three different staining panels for surface markers: for the 24-h
stain, CD3 PerCP (UCH1; BioLegend), CD56-phycoerythrin (PE)
(HCD56; Biolegend), anti-T-cell receptor (TCR) Pan/-PE (IMMU510;
Beckman Coulter), CD4 Pacific Blue (OKT4; Beckman Coulter), CD8
allophycocyanin (APC)-H7 (SK1; BD Pharmingen), CD45RO energy
coupled dye (ECD) (UCH1; Beckman Coulter), and CD62L PeCy7
(DREG56; eBioscience); for the ex vivo stain, the only changes from the
previous stain were CD3 V500 (clone SP342; BD Horizon) and CD8
PerCP (RPA-T8; BioLegend); and for the third-panel 6-day stain, CD3
PeCy7 (OKT3; BioLegend) and CD8 PerCP (RPA-T8; BioLegend). For
intracellular staining, cells were incubated with different monoclonal an-
tibodies (MAbs) depending on the staining panels. After 30 min of incu-
bation at RT, cells were washed and permeabilized with Foxp3 fix/perm
buffer (eBioscience) for 30 min on ice and stained in permeabilization
buffer (eBioscience) with IFN- fluorescein isothiocyanate (FITC)
(4S.B3; eBioscience; 24-h stain) and Foxp3 eF660 (PCH101; eBioscience;
ex vivo stain) or Ki67 FITC (B56; BD Pharmingen) and Foxp3 eF660
(PCH101; eBioscience; 6-day stain). Cells were collected on a CyAn ADP
9-color flow cytometer (Dako/Beckman Coulter) and analyzed using
FlowJo software (Tree Star, Inc.) version 9.6. All assays were conducted
with the same batches of PfRBC and uRBC, with all time points of one
volunteer assayed in one experiment to prevent interassay variations.Nat-
ural killer T cells (NKT) and gamma delta T cells (T) were analyzed in
the same gate and henceforth are referred to as NKT-T cells.
Statistical analysis. Statistical analysis was performed in GraphPad
Prism 5. Differences within the cohorts and between time points were
analyzed per volunteer by aWilcoxonmatched-pairs signed-rank test and
those between groups were analyzed by a Mann-Whitney U test. The
relationship between baseline antibody titers and the increase in antibody
titers was analyzed by Spearman correlation, and P values of0.05 were
considered statistically significant. Cellular responses were corrected for
the background by subtracting responses to uRBC from responses to
PfRBC for each sample; resulting negative values were set to zero.
RESULTS
Tanzanian volunteers have higher baseline antibody titers than
Dutch subjects. Pre-CHMI antibody titers were significantly
higher in Tanzanian than in the malaria-naive Dutch volunteers
for crude P. falciparum lysate (P  0.03), with 12/21 Tanzanians
having titers higher than the mean (2 SD) titers of Dutch vol-
unteers. This was also true for pre-CHMI antibodies to the indi-
vidual parasite antigens AMA-1 (P 0.015; 13/21) and CSP (P
0.04; 15/21), and the same trend was found for EXP-1 (P 0.06;
8/21) (Fig. 1A). Elevated LSA-1 antibody titers were found in 5/21
Tanzanians, but there was no significant difference between Dutch
and Tanzanians at the group level (P 0.16). Within the Tanzania
cohort, therewasawide rangeofpre-CHMIantibodyresponses,with
some volunteers showing only low responses, comparable to those of
the Dutch cohort. To address whether there was a general division
into high and low responders to malaria antigens, we stratified Tan-
zanian individuals based on their reactivity to P. falciparum lysate
(containing a large number of late-liver- and blood-stage antigens)
(Fig. 1B).Compared to theirP. falciparum lysate-seronegative coun-
terparts (n 9), seropositive Tanzanians (n 12) had significantly
higher antibody titers against the cross-stage antigens AMA-1 (P
0.005; 7.6-fold higher median titer) and EXP-1 (P  0.04; 5.4-fold
higher). The same trend was found for the sporozoite antigen CSP
(P  0.09; 2.4-fold higher) and the liver-stage antigen LSA-1 (P 
0.06; 1.7-fold) (Fig. 1C).
P. falciparum lysate seropositivity prior to CHMI is associ-
ated with reduced initial blood-stage parasitemia. We next as-
sessedwhether preexisting humoral responsesmight be associated
with the control of parasites in Tanzanian volunteers. In line with
stronger humoral responses in the Tanzanian cohort than in the
Dutch cohort at baseline, Tanzanian volunteers became qPCR
positive significantly later than the Dutch volunteers (Fig. 2A),
with a median prepatent period of 11.0 days (interquartile range
[IQR], 11.0 to 13.5) in Tanzanians and 10.0 days (9.5 to 11.0) in
Dutch volunteers (P  0.009). Similarly, prepatency by TS was
also longer in Tanzanians (median [IQR], 13.7 days [12.75 to
16.7]) than in the Dutch (12.6 days [12.3 to 14]) (P 0.035). The
time between detection by qPCR and by TS was comparable for
both cohorts (median [IQR] forTanzanians, 2.6 days [2.2 to 3.15];
Dutch, 3.0 days [2.0 to 3.15]; P 0.88), but Dutch volunteers had
a significantly higher peak parasite density (median number of
parasites/milliliter [IQR] for Tanzanians, 12,000 [6,800 to
15,000]; Dutch, 74,000 [26,000 to 190,000]; P  0.02), possibly
due to slight differences in the thick smear protocol between the
two sites. Within the Tanzanian cohort, there was no significant
difference in time to qPCR-detectable parasitemia between volun-
teers who were either P. falciparum lysate seropositive or serone-
gative at baseline (P 0.16) (Fig. 2B), norwas there a difference in
prepatency by TS (P 0.41) or time between detection by qPCR
and TS (P  0.15). However, seropositive Tanzanian volunteers
had a significantly lower parasite load at the time of first qPCR-
detectable parasitemia than their seronegative counterparts (P
0.033) (Fig. 2C). This difference remained evident, but became
smaller, by the time the first peak in parasite loadwas reached (P
0.05; Fig. 2D). Across all Tanzanian volunteers, pre-CHMI anti-
body titers for CSP (Pearson r  0.45, P  0.04), but no other
antigens, correlated significantly with prepatancy by qPCR (see
Fig. S1 in the supplemental material).
P. falciparum-specific antibody responses are more effi-
ciently increased in Tanzanians than in Dutch volunteers after
CHMI. Post-CHMI, antibody responses increased significantly in
the Tanzanian volunteers for P. falciparum lysate (P  0.001;
15/21 with a	3-fold increase in titers), AMA-1 (P 0.002; 6/21),
EXP-1 (P  0.0001; 14/21), LSA-1 (P  0.001; 5/21), and CSP
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(P  0.001; 11/21) (Fig. 3A). In contrast, the Dutch volunteers
showed significant increased titers only against EXP-1 (P 0.004;
7/9), CSP (P  0.008; 6/9), and P. falciparum lysate (P  0.008;
3/9), while responses to LSA-1 and AMA-1 remained low and
unaltered (Fig. 3B). Compared to the Dutch, Tanzanians showed
a trend for stronger induction or boosting of responses based on
the overall fold increase in titers to P. falciparum lysate, AMA-1,
and LSA-1 (Fig. 3C) and significantly higher absolute increases in
titers for these antigens (Fig. 3D). Volunteers in both cohorts were
subjected toCHMIwith either 10,000 or 25,000 PfSPZs.However,
the only significant difference in antibody responses between the
two dose groups was a slightly higher response in the 25,000 than
in the 10,000 dose group for P. falciparum lysate in Dutch volun-
teers (P  0.04) and a similar trend for the Tanzanians for CSP
(P 0.07) (see Fig. S2 in the supplementalmaterial). Post-CHMI,
P. falciparum lysate-seronegative Tanzanians had a significantly
stronger fold increase in antibody titers against AMA-1 (P 0.02)
and EXP-1 (P 0.04) than seropositive individuals, with a similar
trend for P. falciparum lysate (P  0.082) and CSP (P  0.095),
but no difference in LSA-1 responses (P 0.80) (Fig. 3E). For the
entire cohort, the fold increase of P. falciparum lysate (P 0.01)
and AMA-1 (P 0.001) responses upon CHMI correlated nega-
tively with the baseline response. The absolute increase in titers,
however, was not different for any of the antigens between the two
FIG 1 Baseline malaria-specific antibody titers indicate previous exposure in Tanzanian volunteers. Antibody reactivity against crude P. falciparum lysate and
the P. falciparum antigens AMA-1, EXP-1, LSA-1, and CSP was tested prior to malaria infection. A pool of sera from 100 hyperimmune Tanzanians (HIT) was
used as a reference. Reactivity for each antigen in undilutedHIT serumwas set at 100 arbitrary units (AUs). (A) Responses betweenDutch (D; circles; n 9) and
Tanzanian (T; squares; n  21) cohorts were compared using a Mann-Whitney U test. (B) Tanzanian volunteers were stratified based on P. falciparum lysate
recognition at baseline as Sero (n 12; black box plots) or Sero (n 9; white box plots), using themean 2 SD of Dutch volunteers (gray circles) as a cutoff
for positivity. (C) Pre-CHMI responses of seropositive and seronegative Tanzanians were analyzed by ELISA for individual P. falciparum antigens and compared
by Mann-Whitney U test. Scatter plots show individual data points, horizontal lines indicate the median of the group, and error bars indicate the interquartile
range (IQR). Dashed lines indicate the mean 2 SD of antibody titers in Dutch volunteers for each respective antigen.
FIG 2 Preexposure to malaria is associated with difference in prepatency and parasitemia after CHMI. Parasitemia after CHMI was determined by qPCR. The
day of first parasite detection by qPCR after PfSPZ injection is shown for Dutch (D; gray circles; n 9) compared to Tanzanians (T; gray squares; n 21) (A)
and for P. falciparum-seropositive (n 12; black squares) and -seronegative (n 9; white squares) Tanzanian volunteers (B). The parasite load (number of P.
falciparum parasites per milliliter of blood) at the first day of qPCR-detectable parasitemia (C) and the time of first peak parasite density (D) are shown for P.
falciparum-seropositive (n 12; black squares) and -seronegative (n 9; white squares) Tanzanian volunteers. Data are shown as median
 IQR. Groups were
compared by a Mann-Whitney U test.
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groups (Fig. 3F). Notably, P. falciparum lysate-seronegative Tan-
zanians thereby also showed a greater absolute increase in anti-
body titers than malaria-naive Dutch volunteers.
Dutch but not Tanzanian volunteers show cellular recall re-
sponses induced by CHMI. To analyze the acquisition of cellular
responses after CHMI, we investigated in vitro IFN- responses
upon incubation with PfRBC for 24 h (Fig. 4A and B). At baseline,
P. falciparum-specific IFN- responses were comparable between
Dutch and Tanzanians for all cell subsets except for NKT-T
cells, which showed slightly higher responses in the Dutch (P 
FIG3 Increased humoral responses inDutch andTanzanians after CHMI. Antibody titers weremeasured 4weeks (Tanzanians; squares; n 21) (A) and 5weeks
(Dutch; circles;n 9) (B) after intradermal infectionwith PfSPZs.Graphs show the antibody reactivity (AUs) pre-CHMI (black) and post-CHMI (white) against
crude P. falciparum lysate, AMA-1, EXP-1, LSA-1, and CSP. Plots show individual data points, with lines connecting the two time points for each volunteer.
Responses in the two cohorts pre- and post-CHMI were compared by using a Wilcoxon matched-pairs signed-rank test. The fold increase (ratio of AU
post-CHMI/AU pre-CHMI) (C, E) and absolute increase in antibody reactivity (AU post-CHMIminus AU pre-CHMI) (D, F) were calculated for Dutch versus
Tanzanian volunteers (C, D) and in Tanzanian volunteers classified as P. falciparum lysate seropositive or seronegative at baseline (E, F). Data are shown as
whisker plots, with boxes indicating the median and IQR, and whiskers indicating the minimum/maximum values. Responses were compared using a Mann-
Whitney U test.
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FIG 4 Dutch but not Tanzanian volunteers show increased P. falciparum-specific in vitro IFN- production after CHMI. PBMCs collected pre- and post-CHMI
fromDutch (D; circles;n 9; post 35 days afterCHMI) andTanzanian (T; squares;n 21; post 28 days afterCHMI) volunteerswere stimulatedwith PfRBC
for 24 h. (A) After stimulation, cells were stained for surface expression of CD3, CD4, TCR, CD8, and CD56 to gate lymphocyte subsets. NKT and T were
gated as a combined population. (B) Intracellular IFN- is shown for total lymphocytes after 24 h of uRBC or PfRBC stimulation. Graphs show the proportions
of cells with P. falciparum-specific IFN- production, comparing Dutch and Tanzanian volunteers pre-CHMI (C) and post-CHMI (D), and comparing pre- and
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0.077) (Fig. 4C). Post-CHMI, previously malaria-naive Dutch
volunteers showed significant increases in P. falciparum-specific
IFN- production by all lymphocyte subsets analyzed (CD4,P
0.004; CD8, P  0.009; CD56dim, P  0.004; CD56bright NK,
P 0.008; NKT-T, P 0.004) (Fig. 4E to I). In contrast, Tan-
zanian volunteers showed little or no increase in IFN--produc-
ing cells (CD4, P 0.74; CD8, P 0.065; CD56dim, P 0.49;
CD56bright NK, P 0.75; NKT-T, P 0.92). In both cohorts
and at both time points, CD56brightNK cells showed significantly
higher IFN- responses than CD56dimNK cells (Dutch pre/post-
CHMI, P 0.004; Tanzanian pre/post-CHMI, P 0.0001). Sig-
nificantly increased IFN- responses were found in both the effec-
tor (CD4, P 0.004; CD8, P 0.008) and central (CD4, P
0.004; CD8, P  0.012) memory T-cell compartments in the
Dutch cohort, while the Tanzanians showed no such increase (see
Fig. S3 in the supplemental material). As a result, post-CHMI
IFN- responses in the Dutch were significantly higher for all cell
subsets than in the Tanzanian cohort (Fig. 4D). Within the Tan-
zanian cohort, there was an overall trend for higher P. falciparum-
specific pre-CHMI IFN- responses in those volunteers that had
particularly short prepatency by qPCR (see Fig. S1 in the supple-
mental material). CD8 T cells from Dutch (P  0.04) but not
Tanzanian (P  0.47) volunteers showed increased proliferative
responses post-CHMI (see Fig. S4A in the supplementalmaterial).
The proliferation of CD4 T cells in response to PfRBC was not
significantly altered post-CHMI in either cohort (P  0.25 in
Dutch and P 0.11 in Tanzanians) (see Fig. S4B).
Analyzing the lymphocyte subset compositions in both co-
horts, we found that they were largely stable between pre- and
post-CHMI time points, with the exception of a prominent and
significant post-CHMI increase of the NKT-T proportion in
the Dutch volunteers and a clear decrease of CD56dim NK pro-
portions in both cohorts. There was further no significant differ-
ence in the proportions of CD4 CD45RO Foxp3 T cells be-
tween the two cohorts, which could have explained differences in
responsiveness (see Table S1 in the supplemental material). For
the Tanzanian cohort, we observed a significant reduction of
Foxp3 T cells post-CHMI (P 0.008), while for the Dutch vol-
unteers there was no change (P  0.44). Stimulation with the
phorbol myristate acetate (PMA) and ionomycin mitogens
showed that lymphocytes of both Dutch and Tanzanian volun-
teers were fully functional and able to produce IFN- at compa-
rable levels both pre- and post-CHMI (see Fig. S4C).
Reduced innate IFN- responses in Tanzanian volunteers
are associatedwith preexisting humoral immunity and thus po-
tential preexposure. Finally, we analyzed whether the degree of
preexposure reflected by differences in malaria-specific humoral
immunity might affect cellular recall responses to PfRBC. Cells
from P. falciparum lysate-seronegative Tanzanian volunteers had
significantly higher responses to PfRBC (pre-CHMI) than those
from seropositive Tanzanian volunteers (NKT-T, P  0.05;
CD56dim, P  0.01; CD56bright NK, P  0.04) and were of a
magnitude comparable to those observed in the Dutch volunteers
(Fig. 5). CD4 and CD8 T cells showed a similar pattern, al-
though the difference between seropositive and seronegative Tan-
zanians did not reach statistical significance (Fig. 5A and B). Post-
CHMI, these differences remained, and there was no increase in
these responses in either of the two groups.
DISCUSSION
In the present study, we performed a side-by-side comparison of
antimalarial immune responses initiated or recalled by CHMI in
two cohorts of young adults, fromTheNetherlands andTanzania,
with different malaria exposure histories and genetic back-
grounds. Recruitment of Tanzanian volunteers took place in Dar
es Salaam, an urban areawheremalaria is hypoendemic. Inclusion
criteria into this CHMI trial were tailored to ensure minimal re-
cent exposure to P. falciparum: Tanzanian volunteers had not ex-
perienced a clinical episode ofmalaria for 5 years, as self-reported,
and were confirmed free of parasites by qPCR before CHMI took
place. Nevertheless, more than 50% of the 21 Tanzanian volun-
teers had a positive P. falciparum lysate serology before CHMI
post-CHMI responses within each cohort for CD4 T cells (E), CD8 T cells (F), CD56dimNK cells (G), CD56bright NK cells (H), and NKT-T cells (I). For
each volunteer, all time points were measured in a single experiment. Data are shown as whisker plots with boxes indicating the median with IQR and whiskers
the minimum/maximum values (C and D) or individual data points with lines connecting the two time points for each volunteer (E to I). All responses were
corrected for the background by subtracting responses to uRBC. Responses pre-CHMI and post-CHMI were compared using a Wilcoxon matched-pairs
signed-rank test.
FIG 5 P. falciparum-specific in vitro IFN- production by innate lymphocytes from Tanzanian volunteers is dependent on baseline serological status. PBMCs
collected from Tanzanian volunteers who either had a positive P. falciparum (Sero; n  12; black squares) or negative P. falciparum (Sero; n  9; white
squares) serology prior to challenge (baseline) were stimulated with PfRBC for 24 h and stained for intracellular IFN-. Panels show IFN- production by
lymphocyte subsets: (A) CD4 T cells; (B) CD8 T cells; (C) NKT-T cells; (D) CD56dim; (E) CD56bright NK cells. Data are shown as median 
 IQR of
responses corrected for the background by subtracting responses to uRBC. Differences in responses between the seropositive and seronegative groups were
analyzed by aMann-Whitney U test. P. falciparum-specific IFN- responses of pre-CHMI PBMCs frommalaria-naive Dutch volunteers (D; n 9; gray circles),
who had negative P. falciparum serology, are shown as a comparator.
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based on P. falciparum lysate ELISA, which is a standard exclusion
criterion in Dutch CHMI trials. In line with this, increased base-
line antibody titers for the P. falciparum antigens CSP, LSA-1,
EXP-1, and AMA-1 were found in the Tanzania cohort and par-
ticularly in those with positive serology for P. falciparum lysate.
This clearly indicates previous exposure to the malaria parasite in
this cohort. Asymptomatic infections, which can often occur in
people living in areas with low malarial endemicity (34), in the 5
years of no self-reported clinical malaria preceding CHMI might
have led to a maintenance of higher antibody responses.
As might be expected, preexisting antibodies to P. falciparum
antigens appeared to have an effect on the outcome of CHMI.
Tanzanians had a significantly longer prepatency based on qPCR
detection than the previously malaria-naive Dutch. Furthermore,
P. falciparum lysate-seropositive Tanzanians had a lower parasite
load at the time of first detection by qPCR and at the time of the
first peak of parasite load than seronegative Tanzanians. The first
peak of blood-stage parasitemia can be used as a proxy for parasite
liver load (16, 35). Our results might therefore indicate the emer-
gence of fewer parasites from the liver and hence better control of
either initiation or progression of liver-stage infection in preex-
posed individuals within the Tanzanian cohort and in Tanzanians
than in the Dutch cohort. In line with such an effect of preexisting
antisporozoite immunity would be the observation that those
Tanzanian volunteers with a longer prepatancy by qPCR also had
higher baseline antibody titers against the sporozoite antigenCSP.
However, the first detection by qPCR in both the Dutch and Tan-
zanians after intradermal PfSPZ injection was uncharacteristically
late compared to that for infection by mosquito bite routinely
conducted in The Netherlands and elsewhere (11, 16, 18, 19, 23,
24, 35). This is likely due to less efficient liver-stage infection by
this route and hence a low initial blood-stage load that reaches the
qPCR detection limit only later. A lower first detectable para-
sitemia in seropositive Tanzanians than in seronegative Tanzani-
ans might therefore additionally be attributed to the control of
blood-stage replication prior to qPCR detection. Antibodies di-
rected against AMA-1, for instance, are known to interfere with
blood-stage multiplication (36) but can also confer protection
against liver-stage infection (37). Since recognition of both cross-
stage and liver-stage antigens was stronger in the Tanzanian co-
hort than in the Dutch, and particularly in the seropositive indi-
viduals, both possibilities remain open. Our data, however,
support antibody control of blood-stage replication only during
the initial phase of sub-qPCR-detectable parasitemia: while para-
site multiplication based on PCR data could not be directly com-
pared due to the high variability of the amplification dynamics
(24), there was no difference between prepatency by TS and qPCR
in the two Tanzanian groups.
Upon CHMI, Dutch volunteers showed a slight but significant
induction of humoral responses against CSP, P. falciparum lysate,
and EXP-1, while Tanzanians boosted responses to all antigens
examined. Reactivity to the CSP sporozoite antigen is expected
after PfSPZ inoculation and consistent with previous findings (38,
39). Increased antibody responses against P. falciparum lysate and
EXP-1 likely reflect cross-stage reactivity between late-liver-stage
and blood-stage merozoites, while exposure to developing liver
stages (LSA-1) in naive volunteers appears insufficient to induce a
detectable antibody response. Similarly, limited exposure to
blood-stage-expressed AMA-1, due to early curative treatment,
appears to prevent induction of detectable titers in naive volun-
teers, which is consistent with results even after multiple CHMIs
(39). Consistent with preexposure, Tanzanians showed on the
group level a greater increase in titers for P. falciparum lysate,
AMA-1, and LSA-1 than the previously malaria-naive Dutch.
Within the Tanzanian cohort, P. falciparum lysate-seronegative
Tanzanians showed a similar absolute and accordingly much
greater fold increase in antibody titers than their seropositive
counterparts. At baseline, these volunteers had significantly lower
responses to most parasite antigens than their seropositive coun-
terparts and largely resembled the malaria-naive Dutch cohort.
The fact that this group showed a greater increase in antibody
titers than theDutch strongly suggests that despite largely negative
P. falciparum serology, these individuals have a stable P. falci-
parum-specificmemory B-cell repertoire (40, 41). Given the same
increase in absolute antibody titers, their memory B-cell reper-
toire appears to be of a magnitude similar to that of the P. falcip-
arum lysate-seropositive Tanzanians, despite lower circulating
plasma antibody levels.
Of note, humoral responses were assessed using a number of
recombinant or synthetic proteins, which are not fully identical to
the sequences of these proteins expressed by the NF54 strain used
in both CHMI trials. While most antigens used in this study were
of the 3D7 sequence and thus closely resemble theNF54 sequence,
AMA-1 responses were assessed using the FVO strain sequence.
AMA-1 is known for its extensive antigenic polymorphism and to
cause strain-specific immunity (42, 43). Nevertheless, there is a
significant antigenic overlap between AMA-1 alleles allowing for
cross-reactivity across different strains, both in terms of func-
tional activity and recognition, which affects mainly the magni-
tude of the response (42, 44–46). Based on these data, we consider
it unlikely that assessment of AMA-1 responses using the NF54 or
3D7 sequence would have yielded different qualitative results.
However, absolute titers would likely have been higher when us-
ing the AMA-1 sequence homologous to the CHMI strain.
Another potential confounder is the fact that the P. falciparum
strains that Tanzanian volunteers were naturally exposed to prior
to CHMI with P. falciparum NF54 are unknown. As any study
examining preexposed individuals, analysis of antigen-specific re-
sponses against polymorphic antigens has therefore the additional
limitation that it is difficult to match this unknown exposure his-
tory. This has to especially be taken into account when investigat-
ing CHMI-induced boosting of potential preexisting responses in
this cohort, which might be masked by using antigens of different
strain origins. However, despite the fact that Tanzanians likely
experienced exposure to a variety of P. falciparum strains prior to
CHMI, there was (i) a clear division into seropositive and serone-
gative individuals not just by total P. falciparum NF54 lysate but
also by all individual antigens analyzed and (ii) a clearly stron-
ger increase in antibody titers in Tanzanians than in malaria-
naive Dutch volunteers to several antigens, including AMA-1.
We cannot exclude, however, that this might have even been
more pronounced when using antigens of different strain ori-
gins for analysis.
Although the Tanzanian volunteers in the present study
showed evidence of humoral immune memory, parasite-specific
IFN- production by adaptive T-cell subsets was not higher than
in malaria-naive Dutch volunteers at baseline and remained un-
changed after CHMI. In contrast, previously naive Dutch volun-
teers showed a significant increase in IFN- production by CD4
and CD8 T-cell subsets after a primary infection, consistent with
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what has been shown previously (47, 48). The lack of increased
proliferative and Th1 responses 1 month after CHMI in Tanza-
nian volunteers could be partially due to immunosuppression fol-
lowing exposure to blood-stage parasites during CHMI. Such T-
cell immunosuppression is well described for malaria (49–58)
and, although usually resolved within 2 weeks (52, 53), can persist
formore than 4 weeks (50). That Dutch volunteers are not equally
affected by this might be due to the fact that such immunosup-
pressive effects appear to bemore pronounced in immune than in
nonimmune donors, as shown elsewhere (59). T regulatory cells
(Tregs) are one potential mediator of suppressed IFN- produc-
tion by adaptive cells. Increased Treg numbers during or after
malaria are a well-reported phenomenon (60), and malaria para-
sites can enhance the suppressive activity of Tregs (61). While
Dutch and Tanzanian volunteers had similar Treg proportions,
we cannot exclude that Tregs in Tanzanian volunteers might be
functionally more active, potentially due to past priming in ma-
laria infections. That this apparent lack of a Th1 immune response
in the Tanzanian cohort is malaria specific is supported by the fact
Dutch and Tanzanian volunteers showed similar Th1 responses to
mitogen stimulation both pre- and post-CHMI. Nevertheless, an
additional influence of genetic background, which may explain
differential P. falciparum-specific responses described in settings
where malaria is endemic, cannot be excluded (62, 63).
NK cells are rapidly activated by malaria parasites, contribute
to the early IFN- response during blood-stage infection (64), and
can eliminate infected erythrocytes in vivo in a contact-dependent
manner (65). Importantly, there is a functional dichotomy: the
rarer CD56bright cells are more prominent in lymphatic tissues
and are superior cytokine producers, while the CD56dim subset
harbors a stronger cytotoxic potential (66–68). However, NK cells
have usually been examined as one population, and the exact con-
tributions ofCD56dimandCD56brightNK cell subsets tomalaria
immunity thus remain to be established. An in vitro study on
PBMCs frommalaria-naive donors found greater IFN- produc-
tion byCD56bright than byCD56dimNKcells only in response to
cytokines but not upon PfRBC stimulation (69). However, con-
sistent with their generally reported greater cytotoxic potential,
only CD56dim cells showed degranulation upon PfRBC stimula-
tion (69). Our findings that CD56bright NK cells show a greater
IFN- response thanCD56dimNKcells to PfRBCboth before and
after a primarymalaria infection, as well as amemory-like effect of
this response, are in line with findings from a previous CHMI trial
(70). Tanzanian volunteers showed the same functional difference
between the two NK cell subsets but no memory effect in either
subset after CHMI. It was previously shown that depletion ofT
cells abrogates memory-like IFN- responses of innate cells oth-
erwise observed after CHMI (47, 70). Therefore, the absence of
increased PfRBC-specificT-cell responses post-CHMI in Tan-
zania volunteers might be one reason why P. falciparum-specific
IFN- production by NK cells and other innate lymphocytes
(NKT and  T cells) was also not increased post-CHMI. The fact
that P. falciparum lysate-seronegative Tanzanians had higher in-
nate IFN- responses than did seropositive Tanzanians already at
baseline is a further indication that reduced Th1 responses are
likely linked to the degree of previous malaria exposure. Of note,
the proportion of CD56bright cells remained unaltered after
CHMI, while the CD56dim subset had a smaller contribution to
the PBMC compartment post-CHMI in both cohorts. It remains
to be established whether this means that, in contrast to memory-
like IFN- production, other NK cell functions, such asmigration
out of the circulation and engagement in antimalaria immune
responses at other sites, such as the spleen, are unaffected and fully
functional in preexposed individuals.
Within the Tanzanian cohort, there was no association of pre-
existing P. falciparum-specific IFN- responses by T-cell subsets
or innate lymphocytes with the parasitological outcome of CHMI,
i.e., prepatency or parasite load at first detection by qPCR. If at all,
those with higher IFN- responses to blood-stage PfRBC had a
shorter prepatency. This does not, however, exclude that cellular
responses play a role in the prolonged prepatency of Tanzanian
volunteers and specifically those with positive P. falciparum serol-
ogy. One possible reason for the lack of such an association is that
PfRBC were chosen as a stimulus for P. falciparum-specific re-
sponses. This was done due to the relatively large antigenic overlap
betweenblood-stage and (late) liver-stage parasites (71, 72).How-
ever, responses to sporozoite and early-liver-stage antigens, which
may be more relevant when assessing responses responsible for
reducing the parasite load by targeting the earlier stages of infec-
tion, are likely to be missed using PfRBC as a stimulus. Moreover,
our analysis was restricted toP. falciparum-specific IFN-produc-
tion, and it is likely that other responses, for instance, degranula-
tion as a proxy for cytotoxicity, may be more relevant readouts
(71). Finally, the only accessible compartment for analysis of cel-
lular responses in these human trials was peripheral blood. P. fal-
ciparum-specific responses, and particularly those responsible for
reducing liver infection, might, however, be enriched or primarily
located in other sites, for instance, in tissue-resident memory cells
in the liver (73, 74). This might be even more pronounced in
preexposed individuals, where such a tissue-resident memory
population might have already been established.
Noteworthy, the differential immune responses described
herein may explain why Tanzanian volunteers reported fewer
clinical symptoms, such as fever, than their Dutch counterparts
during CHMI after PfSPZ injection (24). On the one hand, pre-
existing antibody responses may reduce the initial parasite load
and mediate antidisease immunity. Additionally, the relatively
lowerP. falciparum-specific cellular Th1 responses observed in the
Tanzanian cohort than in the Dutch cohort might also be benefi-
cial. Dutch volunteers preexposed to infected mosquito bites un-
der chloroquine prophylaxis exhibited stronger IFN- produc-
tion and earlier clinical symptoms when reexposed to blood-stage
parasites thanmalaria-naive volunteers during their first infection
(15). Thus, a shift away from Th1 responses in preexposed volun-
teers maymake them less vulnerable to fever and other inflamma-
tion-induced symptoms.
In conclusion, our data show that previousmalaria exposure is
associated with some degree of parasite control during liver-stage
or early-blood-stage infection after CHMI, humoral immune
memory, and reduced antiparasite Th1 responses in the circulat-
ing lymphocyte compartment. Positive P. falciparum lysate serol-
ogy can be used to identify individuals with better parasite control
but weaker peripheral blood Th1 responses, which may help to
stratify volunteers in future CHMI trials in areas where malaria is
endemic. However, assessment ofmemory B-cell responsesmight
be explored as a potentially better tool than serology to define
preexposure per se. Important questions to be addressed in future
studies include (i) which readouts other than Th1 responses
should be used to determine immunization-induced cellular im-
munity and (ii) how differences in preexisting malaria-specific
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immune responses affect the outcome of whole parasite immuni-
zation and vaccination approaches in areas where malaria is en-
demic.
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